Trogenix has dosed the first patient in its Phase I/II ADePT clinical trial of TGX-007, a dual-payload AAV-based gene therapy for newly diagnosed and recurrent glioblastoma, an aggressive form of brain cancer.
The trial is taking place at NHS Lothian in the UK and Ohio State University Hospital in the US. It will assess the optimal biological dose, safety, efficacy, tumour targeting, immune activation and overall survival in patients with glioblastoma.
TGX-007 uses Trogenix’s Synthetic Super-Enhancer technology to identify cancer cells and switch on therapeutic payloads designed to kill tumour cells while stimulating an immune response. The company describes it as a potential one-time treatment with possible application beyond brain cancer, including colorectal, liver and lung cancers.
The first patient was treated in Edinburgh. Trogenix says the trial builds on preclinical research published in Nature in April 2026, where a single dose of SSE-based therapy eradicated tumours in 83% of treated cases in an aggressive brain cancer model, with no recurrence or toxicity reported over 11 months.
In simple terms: Trogenix has begun human testing of a new precision gene therapy for glioblastoma, aiming to kill brain tumour cells and trigger longer-lasting immune protection from a single treatment.
Credit: Canser Research Horizons